Back
Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.
Journal article

Glicoprotein (GP) IIb/IIIa inhibitors for acute stroke treatment.

  • 2002-11-27
Published in:
  • Clinical and experimental hypertension (New York, N.Y. : 1993). - 2002
Brain Ischemia
Fibrinolytic Agents
Humans
North America
Platelet Activation
Platelet Aggregation Inhibitors
Platelet Glycoprotein GPIIb-IIIa Complex
Randomized Controlled Trials as Topic
Stroke
Tissue Plasminogen Activator
Treatment Outcome
English The benefit of antiplatelet therapy remains unclear, although it does appear that aspirin monotherapy started within 48 hours of stroke onset may result in a modest clinical improvement. Glicoprotein (GP) IIb/IIIa antagonists are currently considered the most powerful specific inhibitors of platelet activation in acute thrombosis. Glicoprotein IIb/IIIa inhibitor therapy could merit a prominent role also in the initial management of patients with acute ischemic stroke. Abciximab may be promising in this setting and should be evaluated in further clinical trials.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://sonar.ch/global/documents/139170
Statistics
Document views: 24 File downloads: